Depression and alterations in hypothalamic-pituitary-adrenal and hypothalamic-pituitary-thyroid axis function in male abstinent methamphetamine abusers

Human Psychopharmacology

Volumn 28, Issue 5, 2013, Pages 477-483

  Li, Su Xia ^a   Yan, Shi Yan ^a   Bao, Yan Ping ^a   Lian, Zhi ^a   Qu, Zhi ^a   Wu, Ya Ping ^a,b   Liu, Zhi Min ^a  

^a PEKING UNIVERSITY   (China)

^b Weinan Teacher's College   (China)

Author keywords

adrenocorticotropic hormone; cortisol; depression; methamphetamine abuse; thyroid stimulating hormone; thyroxine; triiodothyronine

Indexed keywords

CORTICOTROPIN; HYDROCORTISONE; LIOTHYRONINE; METHAMPHETAMINE; THYROTROPIN; THYROXINE;

ABSTINENCE; ADULT; ARTICLE; BECK DEPRESSION INVENTORY; BLOOD SAMPLING; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DEPRESSION; FEEDBACK SYSTEM; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS THYROID SYSTEM; LIOTHYRONINE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SUBSTANCE ABUSE; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL;

ADRENOCORTICOTROPIC HORMONE; CORTISOL; DEPRESSION; METHAMPHETAMINE ABUSE; THYROID-STIMULATING HORMONE; THYROXINE; TRIIODOTHYRONINE;

ADOLESCENT; ADULT; AMPHETAMINE-RELATED DISORDERS; DEPRESSION; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; METHAMPHETAMINE; PITUITARY-ADRENAL SYSTEM; THYROID GLAND; YOUNG ADULT;

EID: 84884134022     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2335     Document Type: Article

References (71)

1. Altshuler LL, Bauer M, Frye MA, et al,. 2001. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry 158 (10): 1617-1622.
2. Aronson R, Offman HJ, Joffe RT, Naylor CD,. 1996. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry 53 (9): 842-848.
3. Baker A, Lee NK, Claire M, et al,. 2005. Brief cognitive behavioural interventions for regular amphetamine users: a step in the right direction. Addiction 100 (3): 367-378.
4. Bamford NS, Zhang H, Joyce JA, et al,. 2008. Repeated exposure to methamphetamine causes long-lasting presynaptic corticostriatal depression that is renormalized with drug readministration. Neuron 58 (1): 89-103.
5. Cadet JL, Krasnova IN,. 2007. Interactions of HIV and methamphetamine: cellular and molecular mechanisms of toxicity potentiation. Neurotox Res 12 (3): 181-204.
6. Cadet JL, Ali S, Epstein C,. 1994. Involvement of oxygen-based radicals in methamphetamine-induced neurotoxicity: evidence from the use of CuZnSOD transgenic mice. Ann N Y Acad Sci 738 (1): 388-391.
7. Cadet JL, Jayanthi S, Deng X,. 2003. Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis. FASEB J 17 (13): 1775-1788.
8. Cadet JL, Krasnova IN, Jayanthi S, Lyles J,. 2007. Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. Neurotox Res 11 (3-4): 183-202.
9. Chang L, Ernst T, Speck O, et al,. 2002. Perfusion MRI and computerized cognitive test abnormalities in abstinent methamphetamine users. Psychiatry Res 114 (2): 65-79.
10. Chang L, Alicata D, Ernst T, Volkow N,. 2007. Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. Addiction 102 (Suppl 1): 16-32.
11. Cleare AJ, McGregor A, Chambers SM, Dawling S, O'Keane V,. 1996. Thyroxine replacement increases central 5-hydroxytryptamine activity and reduces depressive symptoms in hypothyroidism. Neuroendocrinology 64 (1): 65-69.
12. Davidson C, Gow AJ, Lee TH, Ellinwood EH,. 2001. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev 36 (1): 1-22.
13. Ernst T, Chang L, Leonido-Yee M, Speck O,. 2000. Evidence for long-term neurotoxicity associated with methamphetamine abuse: A 1H MRS study. Neurology 54 (6): 1344-1349.
14. Freese TE, Miotto K, Reback CJ,. 2002. The effects and consequences of selected club drugs. J Subst Abuse Treat 23 (2): 151-156.
15. Friedman S, Castaneda E, Hodge GK,. 1998. Long-term monoamine depletion, differential recovery, and subtle behavioral impairment following methamphetamine-induced neurotoxicity. Pharmacol Biochem Behav 61 (1): 35-44.
16. Gerra G, Bassignana S, Zaimovic A, et al,. 2003. Hypothalamic-pituitary- adrenal axis responses to stress in subjects with 3,4-methylenedioxy- methamphetamine ('ecstasy') use history: correlation with dopamine receptor sensitivity. Psychiatry Res 120 (2): 115-124.
17. Gold MS, Pottash AL, Extein I,. 1981. Hypothyroidism and depression. Evidence from complete thyroid function evaluation. JAMA 245 (19): 1919-1922.
18. Gold MS, Kobeissy FH, Wang KK, et al,. 2009. Methamphetamine- and trauma-induced brain injuries: comparative cellular and molecular neurobiological substrates. Biol Psychiatry 66 (2): 118-127.
19. Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, et al,. 1999. Psychopathological, neuroendocrine and autonomic effects of 3,4- methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacology (Berl) 142 (1): 41-50.
20. Grace CE, Schaefer TL, Herring NR, et al,. 2008. (+)-Methamphetamine increases corticosterone in plasma and BDNF in brain more than forced swim or isolation in neonatal rats. Synapse 62 (2): 110-121.
21. Harris D, Reus VI, Wolkowitz OM, Mendelson JE, Jones RT,. 2005. Repeated psychological stress testing in stimulant-dependent patients. Prog Neuropsychopharmacol Biol Psychiatry 29 (5): 669-677.
22. Itzhak Y, Ali SF,. 1996. The neuronal nitric oxide synthase inhibitor, 7-nitroindazole, protects against methamphetamine-induced neurotoxicity in vivo. J Neurochem 67 (4): 1770-1773.
23. Iudicello JE, Woods SP, Vigil O, et al,. 2010. Longer term improvement in neurocognitive functioning and affective distress among methamphetamine users who achieve stable abstinence. J Clin Exp Neuropsychol 32 (7): 704-718.
24. Jayanthi S, Deng X, Ladenheim B, et al,. 2005. Calcineurin/NFAT-induced up-regulation of the Fas ligand/Fas death pathway is involved in methamphetamine-induced neuronal apoptosis. Proc Natl Acad Sci USA 102 (3): 868-873.
25. Jernigan TL, Gamst AC, Archibald SL, et al,. 2005. Effects of methamphetamine dependence and HIV infection on cerebral morphology. Am J Psychiatry 162 (8): 1461-1472.
26. Johanson CE, Frey KA, Lundahl LH, et al,. 2006. Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology (Berl) 185 (3): 327-338.
27. Kalechstein AD, Newton TF, Longshore D, Anglin MD, van Gorp WG, Gawin FH,. 2000. Psychiatric comorbidity of methamphetamine dependence in a forensic sample. J Neuropsychiatry Clin Neurosci 12 (4): 480-484.
28. Kieburtz K, Ketonen L, Cox C, et al,. 1996. Cognitive performance and regional brain volume in human immunodeficiency virus type 1 infection. Arch Neurol 53 (2): 155-158.
29. King G, Alicata D, Cloak C, Chang L,. 2010. Psychiatric symptoms and HPA axis function in adolescent methamphetamine users. J Neuroimmune Pharmacol 5 (4): 582-591.
30. Kramer JC, Fischman VS, Littlefield DC,. 1967. Amphetamine abuse. Pattern and effects of high doses taken intravenously. JAMA 201 (5): 305-309.
31. Krasnova IN, Cadet JL,. 2009. Methamphetamine toxicity and messengers of death. Brain Res Rev 60 (2): 379-407.
32. Laasonen-Balk T, Kuikka J, Viinamaki H, Husso-Saastamoinen M, Lehtonen J, Tiihonen J,. 1999. Striatal dopamine transporter density in major depression. Psychopharmacology (Berl) 144 (3): 282-285.
33. Ladenheim B, Krasnova IN, Deng X,. 2000. Methamphetamine-induced neurotoxicity is attenuated in transgenic mice with a null mutation for interleukin-6. Mol Pharmacol 58 (6): 1247-1256.
34. Lehto SM, Tolmunen T, Kuikka J, et al,. 2008. Midbrain serotonin and striatum dopamine transporter binding in double depression: a one-year follow-up study. Neurosci Lett 441 (3): 291-295.
35. London ED, Simon SL, Berman SM, et al,. 2004. Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry 61 (1): 73-84.
36. Madden LJ, Flynn CT, Zandonatti MA,. 2005. Modeling human methamphetamine exposure in nonhuman primates: chronic dosing in the rhesus macaque leads to behavioral and physiological abnormalities. Neuropsychopharmacology 30 (2): 350-359.
37. McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA,. 1998. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci 18 (20): 8417-8422.
38. Meredith CW, Jaffe C, Ang-Lee K, Saxon AJ,. 2005. Implications of chronic methamphetamine use: a literature review. Harv Rev Psychiatry 13 (3): 141-154.
39. Mirecki A, Fitzmaurice P, Ang L, et al,. 2004. Brain antioxidant systems in human methamphetamine users. J Neurochem 89 (6): 1396-1408.
40. Moon M, Do KS, Park J, Kim D,. 2007. Memory impairment in methamphetamine dependent patients. Int J Neurosci 117 (1): 1-9.
41. Nakama H, Chang L, Cloak C, Jiang C, Alicata D, Haning W,. 2008. Association between psychiatric symptoms and craving in methamphetamine users. Am J Addict 17 (5): 441-446.
42. Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M,. 1988. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry 45 (6): 577-579.
43. Nemeroff CB, Bissette G, Akil H, Fink M,. 1991. Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotrophin-releasing factor, beta-endorphin and somatostatin. Br J Psychiatry 158 (1): 59-63.
44. Newberg A, Amsterdam J, Shults J,. 2007. Dopamine transporter density may be associated with the depressed affect in healthy subjects. Nucl Med Commun 28 (1): 3-6.
45. Newton TF, Kalechstein AD, Kalechstein AD, Duran S, Vansluis N, Ling W,. 2004. Methamphetamine abstinence syndrome: preliminary findings. Am J Addict 13 (3): 248-255.
46. Pariante CM, Lightman SL,. 2008. The HPA axis in major depression: classical theories and new developments. Trends Neurosci 31 (9): 464-468.
47. Peck JA, Reback CJ, Yang X, Rotheram-Fuller E, Shoptaw S,. 2005. Sustained reductions in drug use and depression symptoms from treatment for drug abuse in methamphetamine-dependent gay and bisexual men. J Urban Health 82 (1 Suppl 1): i100-108.
48. Perona MT, Waters S, Hall FS, et al,. 2008. Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions. Behav Pharmacol 19 (5-6): 566-574.
49. Rawson RA, Gonzales R, Brethen P,. 2002a. Treatment of methamphetamine use disorders: an update. J Subst Abuse Treat 23 (2): 145-150.
50. Rawson RA, Huber A, Brethen P, et al,. 2002b. Status of methamphetamine users 2-5 years after outpatient treatment. J Addict Dis 21 (1): 107-119.
51. Ricaurte GA, Schuster CR, Seiden LS,. 1980. Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study. Brain Res Brain Res Rev 193 (1): 153-163.
52. Ricaurte GA, Guillery RW, Seiden LS, Schuster CR, Moore RY,. 1982. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res 235 (1): 93-103.
53. Riehman KS, Iguchi MY, Anglin MD,. 2002. Depressive symptoms among amphetamine and cocaine users before and after substance abuse treatment. Psychol Addict Behav 16 (4): 333-337.
54. Sarchiapone M, Carli V, Camardese G, et al,. 2006. Dopamine transporter binding in depressed patients with anhedonia. Psychiatry Res 147 (2-3): 243-248.
55. Schmitz Y, Schmauss C, Sulzer D,. 2002. Altered dopamine release and uptake kinetics in mice lacking D2 receptors. J Neurosci 22 (18): 8002-8009.
56. Scott LV, Dinan TG,. 1998. Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: implications for the pathophysiology of depression. Life Sci 62 (22): 1985-1998.
57. Scott JC, Woods SP, Matt GE, et al,. 2007. Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev 17 (3): 275-297.
58. Sekine Y, Iyo M, Ouchi Y, et al,. 2001. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 158 (8): 1206-1214.
59. Sekine Y, Minabe Y, Ouchi Y, et al,. 2003. Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. Am J Psychiatry 160 (9): 1699-1701.
60. Sekine Y, Ouchi Y, Sugihara G, et al,. 2008. Methamphetamine causes microglial activation in the brains of human abusers. J Neurosci 28 (22): 5756-5761.
61. Semple SJ, Grant I, Patterson TL,. 2004. Female methamphetamine users: social characteristics and sexual risk behavior. Women Health 40 (3): 35-50.
62. Semple SJ, Zians J, Strathdee SA, Patterson TL,. 2007. Psychosocial and behavioral correlates of depressed mood among female methamphetamine users. J Psychoactive Drugs 39 (Suppl 4): 353-366.
63. Simon SL, Domier CP, Sim T, Richardson K, Rawson RA, Ling W,. 2002. Cognitive performance of current methamphetamine and cocaine abusers. J Addict Dis 21 (1): 61-74.
64. Sinha R, Fuse T, Aubin LR, O'Malley SS,. 2000. Psychological stress, drug-related cues and cocaine craving. Psychopharmacology (Berl) 152 (2): 140-148.
65. Sinha R, Talih M, Malison R, Cooney N, Anderson GM, Kreek MJ,. 2003. Hypothalamic-pituitary-adrenal axis and sympatho-adreno-medullary responses during stress-induced and drug cue-induced cocaine craving states. Psychopharmacology (Berl) 170 (1): 62-72.
66. Torres GE, Gainetdinov RR, Caron MG,. 2003. Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci 4 (1): 13-25.
67. Villemagne V, Yuan J, Wong DF, et al,. 1998. Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. J Neurosci 18 (1): 419-427.
68. Volkow ND, Chang L, Wang GJ, et al,. 2001a. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry 158 (12): 2015-2021.
69. Volkow ND, Chang L, Wang GJ, et al,. 2001b. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 21 (23): 9414-9418.
70. Wilson JM, Kalasinsky KS, Levey AI, et al,. 1996. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2 (6): 699-703.
71. Yang YK, Yeh TL, Yao WJ, et al,. 2008. Greater availability of dopamine transporters in patients with major depression-a dual-isotope SPECT study. Psychiatry Res 162 (3): 230-235.